Search Results - "Yang, J.C.H"

3082 The highly selective c-Met inhibitor tepotinib in combination with gefitinib is active in Asian patients with c-Met-positive EGFR mutant NSCLC by Soo, R.A, Kim, D.W, Yang, J.C.H, Stammberger, U, Xiong, H, Ihling, C, Wu, Y.L

Get full text

Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7) by Hirsh, V, Park, K, Tan, E.H, Zhang, L, O’Byrne, K, Boyer, M, Yang, J.C.H, Mok, T, Lee, K.H, Lu, S, Shi, Y, Kim, S.W, Laskin, J, Kim, D.W, Laurie, S.A, Kölbeck, K, Fan, J, Dodd, N, Märten, A, Paz-Ares, L

Get full text

EGFR Mutation Status Is Associated With Better Radiographic Response and Predicts Favorable Outcomes in Non-Small Cell Lung Cancer Patients With Brain Metastases Treated by Stereotactic Radiosurgery by Yang, W.C, Xiao, F.R, Shih, J.Y, Ho, C.C, Chen, Y.F, Tseng, H.M, Chen, K.Y, Liao, W.Y, Yu, C.J, Yang, J.C.H, Kuo, S.H, Cheng, J.C.H, Yang, P.C, Hsu, F.M

Get full text

213 A phase I dose-finding study of BI 853520, a potent and selective inhibitor of focal adhesion kinase (FAK), in Japanese and Taiwanese patients with advanced or metastatic solid tumors by Doi, T, Lin, C.C, Ohtsu, A, Yang, J.C.H, Shitara, K, Pronk, L.C, Sarashina, A, Cheng, A.L

Get full text

First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials by Schuler, M, Paz-Ares, L, Sequist, L.V, Tan, E.H, Mok, T, Hirsh, V, O’Byrne, K, Zhang, L, Yamamoto, N, Boyer, M, Shah, R, Bennouna, J, Dickgreber, N.J, De Grève, J, Love, J, Märten, A, Fan, J, Ehrnrooth, E, Park, K, Yang, J.C.H

Get full text

Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors or lymphoma by Lin, C.C, Su, W.C, Chao, Y, Lee, J.H, Hsu, C.H, Cheng, A.L, Chung, W.P, Chen, M.H, Lin, C.L, Ho, H.L, Huang, L.P, Huang, C.T, Hsueh, S.P, Yang, J.C.H

“…Background: This phase 1 dose-escalation trial, using a 3+3 design, was conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary…”
Get full text

3113 AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): Pooled analysis from two Phase II studies by Goss, G.D, Yang, J.C.H, Ahn, M.J, Tsai, C.M, Bazhenova, L, Sequist, L.V, Ramalingam, S.S, Shepherd, F.A, Ghiorghiu, S, Cantarini, M, Mann, H, Mitsudomi, T, Jänne, P.A

Get full text

3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies by Ahn, M.J, Tsai, C.M, Yang, J.C.H, Shepherd, F.A, Satouchi, M, Kim, D.W, Bazhenova, L, Hirashima, T, Rukazenkov, Y, Cantarini, M, Mann, H, Ramalingam, S.S, Mitsudomi, T, Jänne, P.A, Goss, G.D

Get full text

3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC) by Barlesi, F, Dingemans, A.M.C, Ou, I, Ahn, J.S, Petris, L.D, Kim, D.W, Yang, J.C.H, Hughes, B, Lena, H, Moro-Sibilot, D, Bearz, A, Viteri, S, Mekhail, T, Spira, A, Zeaiter, A, Bordogna, W, Sturm, C, Golding, S, Morcos, P.N, Govindan, R

Get full text

9134 POSTER Tumour Response, Skin Rash and Health-related Quality of Life (HRQoL) – Post-hoc Data From the IPASS Study by Wu, Y, Fukuoka, M, Mok, T.S.K, Saijo, N, Thongprasert, S, Yang, J.C.H, Chu, D.T, Yang, J.J, Rukazenkov, Y

Get full text

A Prospective Study for Circulating Exosome Integrins in Brain Metastases Identifies Exosomal β3 Integrin As a Novel Prognostic Biomarker after Palliative Whole-Brain Radiotherapy in Lung Cancer by Hsu, F.M., Chen, Y.F., Yang, J.C.H., Cheng, J.C.H.

Get full text

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer by Passaro, A., Leighl, N., Blackhall, F., Popat, S., Kerr, K., Ahn, M.J., Arcila, M.E., Arrieta, O., Planchard, D., de Marinis, F., Dingemans, A.M., Dziadziuszko, R., Faivre-Finn, C., Feldman, J., Felip, E., Curigliano, G., Herbst, R., Jänne, P.A., John, T., Mitsudomi, T., Mok, T., Normanno, N., Paz-Ares, L., Ramalingam, S., Sequist, L., Vansteenkiste, J., Wistuba, I.I., Wolf, J., Wu, Y.L., Yang, S.R., Yang, J.C.H., Yatabe, Y., Pentheroudakis, G., Peters, S.

“…The European Society for Medical Oncology (ESMO) held a virtual consensus-building process on epidermal growth factor receptor (EGFR)-mutant non-small-cell…”
Get full text

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS by Park, K., Vansteenkiste, J., Lee, K.H., Pentheroudakis, G., Zhou, C., Prabhash, K., Seto, T., Voon, P.J., Tan, D.S.W., Yang, J.C.H., Wang, J., Babu, K. Govind, Nakayama, Y., Alip, A., Chua, K.L.M., Cheng, J.C.-H., Senan, S., Ahn, Y.C., Kim, T.-Y., Ahn, H.K., Peters, S., Yoshino, T., Douillard, J.-Y.

“…The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of early…”
Get full text

Clinical Outcome and Toxicity Predictors of Thoracic Re-irradiation for Locoregionally Recurrent Lung Cancer by Yang, W.C., Hsu, F.M., Chen, Y.H., Shih, J.Y., Yang, J.C.H., Cheng, A.L., Kuo, S.H.

Get full text

349 - Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors or lymphoma by Lin, C.C., Su, W.C., Chao, Y., Lee, J.H., Hsu, C.H., Cheng, A.L., Chung, W.P., Chen, M.H., Lin, C.L., Ho, H.L., Huang, L.P., Huang, C.T., Hsueh, S.P., Yang, J.C.H.

Get full text

2060 - Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7) by Hirsh, V., Park, K., Tan, E.H., Zhang, L., O’Byrne, K., Boyer, M., Yang, J.C.H., Mok, T., Lee, K.H., Lu, S., Shi, Y., Kim, S.W., Laskin, J., Kim, D.W., Laurie, S.A., Kölbeck, K., Fan, J., Dodd, N., Märten, A., Paz-Ares, L.

Get full text

1991 - First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials by Schuler, M., Paz-Ares, L., Sequist, L.V., Tan, E.H., Mok, T., Hirsh, V., O’Byrne, K., Zhang, L., Yamamoto, N., Boyer, M., Shah, R., Bennouna, J., Dickgreber, N.J., De Grève, J., Love, J., Märten, A., Fan, J., Ehrnrooth, E., Park, K., Yang, J.C.H.

Get full text